Company Overview and News

0
Elpro International to sell nearly 1.33 per cent stake in PNB MetLife

2018-05-08 thehindubusinessline
Elpro International has agreed to sell approximately 1.33 per cent shareholding in PNB MetLife India Insurance Company for a total consideration of ₹134.22 crore. The decision is subject to satisfaction of certain conditions, including approval from the Insurance Regulatory and Development Authority of India and the Competition Commission of India. Elpro International has been holding 12.75 per cent stake in PNB MetLife Insurance since 2003.
504000 ELPROINTL 512068 DECNGOLD

0
Cresta Fund sells 19.76 lakh shares of Elpro International

2018-03-28 moneycontrol
On March 27, 2018 Cresta Fund sold 19,76,851 shares of Elpro International at Rs 48 on the BSE.
504000 ELPROINTL

0
Elpro’s ₹100-crore rights issue opens

2018-03-27 thehindubusinessline
The rights issue of Elpro International will open on Wednesday and close on April 11. It plans to raise up to ₹100 crore through the rights issue by offering 3.11 crore shares at ₹32.10 a share. The entitlement ratio is nine equity shares for every 40 held by existing shareholders in the company as on February 9. Meanwhile, exchange disclosures reveal that its promoters have been increasing their stakes in the firm through creeping acquisitions in the last few days.
504000 ELPROINTL 532693 PUNJLLOYD

0
The top buzzing midcap stocks to trade on March 19

2018-03-20 moneycontrol
Here are some of the top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. Keep an eye on Cipla, Elpro International, Gujarat State Petroleum Corporation (GSPL) and Binani Industries.
504000 ELPROINTL GUJGAS BINANIIND 539336 500059

0
Elpro to sell 1.25% equity in MetLife for Rs 125 crore

2018-03-19 moneycontrol
Elpro International today said it will offload 1.25 percent of its equity stake in PNB MetLife insurance company, which may fetch it about Rs 125 crore.
504000 ELPROINTL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...